Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: An analysis of the JSHCT

Bone Marrow Transplantation

Volumn 49, Issue 3, 2014, Pages 355-360

  Murata, M ^a   Nishida, T ^a   Taniguchi, S ^b   Ohashi, K ^c   Ogawa, H ^d   Fukuda, T ^e   Mori, T ^f   Kobayashi, H ^g   Nakaseko, C ^h   Yamagata, N ⁱ   Morishima, Y ^j   Nagamura Inoue, T ^k   Sakamaki, H ^c   Atsuta, Y ^a   Suzuki, R ^a,b   Naoe, T ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NAGANO RED CROSS HOSPITAL   (Japan)

^h CHIBA UNIVERSITY HOSPITAL   (Japan)

ⁱ Takanohara Central Hospital   (Japan)

^j AICHI CANCER CENTER HOSPITAL   (Japan)

^k UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

donor source; engraftment; hematopoietic SCT; idiopathic myelofibrosis; survival

Indexed keywords

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; CORD BLOOD STEM CELL TRANSPLANTATION; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOID METAPLASIA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; UMBILICAL CORD BLOOD; ALLOTRANSPLANTATION; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CAUSE OF DEATH; CYTOLOGY; FETUS BLOOD; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; JAPAN; MEDICAL SOCIETY; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PRIMARY MYELOFIBROSIS; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; REGISTER; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CAUSE OF DEATH; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; FETAL BLOOD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; JAPAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PRIMARY MYELOFIBROSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REGISTRIES; RETROSPECTIVE STUDIES; SOCIETIES, MEDICAL; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904243249     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.180     Document Type: Article

References (36)

1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255-1265.
2. Barosi G, Hoffman R. Idiopathic myelofibrosis. Semin Hematol 2005; 42: 248-258.
3. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895-2901.
4. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703-1708.
5. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392-397.
6. Ballen K. How to manage the transplant question in myelofibrosis. Blood Cancer J 2012; 2: e59.
7. Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88: 141-150.
8. Harrison C, Verstovsek S, McMullin MF, Mesa R. Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure? Br J Haematol 2012; 157: 426-437.
9. McLornan DP, Mead AJ, Jackson G, Harrison CN. Allogeneic stem cell transplantation for myelofibrosis in 2012. Br J Haematol 2012; 157: 413-425.
10. Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010; 16: 358-367.
11. Kröger N, Holler E, Kobbe G, Bornhäuser M, Schwerdtfeger R, Baurmann H et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264-5270.
12. Zang DY, Deeg HJ. Allogeneic hematopoietic cell transplantation for patients with myelofibrosis. Curr Opin Hematol 2009; 16: 140-146.
13. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761-770.
14. Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol 2007; 86: 269-274.
15. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
16. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
17. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367-369.
18. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
20. Cox DR. Regression models and life tables. J Royal Stat Soc [B] 1972; 34: 187-220.
21. Kerbauy DM, Gooley TA, Sale GE, Flowers ME, Doney KC, Georges GE et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofi-brosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 2007; 13: 355-365.
22. Patriarca F, Bacigalupo A, Sperotto A, Isola M, Soldano F, Bruno B et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 2008; 93: 1514-1522.
23. Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010; 116: 3572-3581.
24. Robin M, Tabrizi R, Mohty M, Furst S, Michallet M, Bay JO et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Socié té Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Br J Haematol 2011; 152: 331-339.
25. Alchalby H, Yunus DR, Zabelina T, Kobbe G, Holler E, Bornhäuser M et al. Risk models predicting survival after reduced-intensity transplantation for myelofi-brosis. Br J Haematol 2012; 157: 75-85.
26. Scott BL, Gooley TA, Sorror ML, Rezvani AR, Linenberger ML, Grim J et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood 2012; 119: 2657-2664.
27. Bacigalupo A, Soraru M, Dominietto A, Pozzi S, Geroldi S, Van Lint MT et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 2010; 45: 458-463.
28. Takagi S, Ota Y, Uchida N, Takahashi K, Ishiwata K, Tsuji M et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis. Blood 2010; 116: 649-652.
29. Stewart WA, Pearce R, Kirkland KE, Bloor A, Thomson K, Apperley J et al. The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplant 2010; 45: 1587-1593.
30. Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate-or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4115-4119.
31. Lissandre S, Bay JO, Cahn JY, Porcher R, Cacheux V, Cabrespine A et al. Retrospective study of allogeneic haematopoietic stem-cell transplantation for mye-lofibrosis. Bone Marrow Transplant 2011; 46: 557-561.
32. Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102: 3912-3918.
33. Devine SM, Hoffman R, Verma A, Shah R, Bradlow BA, Stock W et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99: 2255-2258.
34. Hessling J, Kröger N, Werner M, Zabelina T, Hansen A, Kordes U et al. Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 119: 769-772.
35. Kröger N, Zabelina T, Schieder H, Panse J, Ayuk F, Stute N et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005; 128: 690-697.
36. Merup M, Lazarevic V, Nahi H, Andreasson B, Malm C, Nilsson L et al. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol 2006; 135: 367-373.